Review Articles on Alzheimer's Disease
======================================

Article 1
---------

Jacqueline Birks. Cholinesterase inhibitors for Alzheimerâ€™s disease. Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD005593. DOI: 10.1002/14651858.CD005593.


### General Conclusions

- claims. "The cholinesterase inhibitor donepezil is efficacious for treating mild to moderate Alzheimer's disease."
- claims. "The cholinesterase inhibitor galantamine is efficacious for treating mild to moderate Alzheimer's disease."
- claims. "The cholinesterase inhibitor rivastigmine is efficacious for treating mild to moderate Alzheimer's disease."
- claims. "The three cholinesterase inhibitors donepezil, galantamine, and rivastigmine have about the same efficacy for treating mild to moderate Alzheimer's disease."
- claims. "Out of the two cholinesterase inhibitors donepezil and rivastigmine, donepezil leads to fewer adverse events when used for treating mild to moderate Alzheimer's disease."


### Summarized Outcomes

- claims. 1,2: "The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine improves the patients' cognitive function."
- claims. 3,4: "The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine improves the patients' abilities to carry out activities of daily living."
- claims. 5: "The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine reduces the patients' behavioral disturbance from the disease."
- claims. 6-8: "The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine improves the global assessment of the patients' conditions."
- claims. 11-53: "The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine leads to an increased probability of many types of adverse events."


### Outcomes

Pattern for adverse event sentences:

- TEMPLATE. "The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of at least one adverse event of ADVERSE-EVENT before the end of the treatment as compared to a placebo treatment."

Significant:

- claims. 1: "The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine improves the patients' score on the Alzheimer's Disease Assessment Scale (ADAS-Cog)."
- claims. 2: "The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine improves the patients' score in the Mini Mental State Examination (MMSE)."
- claims. 3: "The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine improves the patients' score in the Disability Assessment for Dementia (DAD)."
- claims. 4: "The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine improves the patients' score in the Progressive Deterioration Scale (PDS)."
- claims. 5: "The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine improves the patients' score obtained by the Neuropsychiatric Instrument (NPI)."
- claims. 6,7: "The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine improves the patients' score in the Clinician's Interview-Based Impression of Change scale (CIBIC-Plus)."
- claims. 10 (subsumes 11): "The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of the patient's withdrawal before the end of the treatment as compared to a placebo treatment."
- claims. 11: "The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of the patient's withdrawal due to an adverse event before the end of the treatment as compared to a placebo treatment."
- claims. 12 (subsumes 13-53): "The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of adverse events before the end of the treatment as compared to a placebo treatment."
- claims. 13: "The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine has a higher probability of at least one adverse event of abdominal pain before the end of the treatment as compared to a placebo treatment."
- claims. 14: "... adverse event of abnormal gait ..."
- claims. 15: "... adverse event of abnormal dreams ..."
- claims. 16: "... adverse event of accidental injury ..."
- claims. 17: "... adverse event of agitation ..."
- claims. 18: "... adverse event of anorexia ..."
- claims. 19: "... adverse event of anxiety ..."
- claims. 20: "... adverse event of arthralgia ..."
- claims. 21: "... adverse event of asthenia ..."
- claims. 22: "... adverse event of back pain ..."
- claims. 23: "... adverse event of confusion ..."
- claims. 24: "... adverse event of conjunctivitis ..."
- claims. 25: "... adverse event of constipation ..."
- claims. 26: "... adverse event of depression ..."
- claims. 27: "... adverse event of diarrhoea ..."
- claims. 28: "... adverse event of dizziness ..."
- claims. 29: "... adverse event of ecchymosis ..."
- claims. 30: "... adverse event of fatigue ..."
- claims. 31: "... adverse event of fever ..."
- claims. 32: "... adverse event of fracture ..."
- claims. 33: "... adverse event of haemorrhage ..."
- claims. 34: "... adverse event of headache ..."
- claims. 35: "... adverse event of hostility ..."
- claims. 36: "... adverse event of increased cough ..."
- claims. 37: "... adverse event of infection ..."
- claims. 38: "... adverse event of insomnia ..."
- claims. 39: "... adverse event of muscle cramp ..."
- claims. 40: "... adverse event of myasthenia ..."
- claims. 41: "... adverse event of nausea ..."
- claims. 42: "... adverse event of pain ..."
- claims. 43: "... adverse event of peripheral oedema ..."
- claims. 44: "... adverse event of rash ..."
- claims. 45: "... adverse event of respiratory tract infection ..."
- claims. 46: "... adverse event of rhinitis ..."
- claims. 47: "... adverse event of skin ulcer ..."
- claims. 48: "... adverse event of syncope ..."
- claims. 49: "... adverse event of tremor ..."
- claims. 50: "... adverse event of urinary tract infection ..."
- claims. 51: "... adverse event of vertigo ..."
- claims. 52: "... adverse event of vomiting ..."
- claims. 53: "... adverse event of weight loss ..."

Not significant:

- reviews. 8: "The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine improves the patients' score in the Gottfries, Brane, and Steen scale (GBS)."
- reviews. 9: "The treatment of Alzheimer's disease with one of the three cholinesterase inhibitors donepezil, galantamine or rivastigmine reduces the time needed by carers to assist in instrumental activities of daily living and physical self-maintenance."


### Individual Studies

RIV-B304:

- "Individual doses in the range 2-12mg/d of rivastigmine b.i.d. or t.i.d. for 26 weeks are efficacious and safe for treating patients with probable Alzheimer's disease."

...

